Vertex Pharmaceuticals Incorporated (VRTX) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Biotechnology
Vertex Pharmaceuticals Incorporated (VRTX) Profile & Business Summary
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Key Information
| Ticker | VRTX |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://www.vrtx.com |
Market Trend Overview for VRTX
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-03-25 (ET)
As of 2026-03-25, VRTX is showing signs of slowing down. Over the longer term, the trend remains bullish.
VRTX last closed at 454.97. The price is about 0.6 ATR below its recent average price (461.27), and the market is currently in a trend that may be losing strength. Price at 454.97 is near light support around 454.40. Momentum may slow, while minor resistance sits near 463.78. View Support & Resistance from Options
The broader uptrend is still intact, but price has moved far from its recent average, increasing the risk of a pullback.
Trend score: 55 out of 100. Overall alignment is unclear. The market is currently in a late-stage trend that may be losing strength. The longer-term trend is still positive, but short-term signals are not yet confirming it.
A key downside level is near 432.89. If price falls below this area, the current upward trend would likely weaken or break.
On 2026-03-17, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-03-02] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
There was no clear sign of meaningful positions being carried into the overnight session.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This reading is based on the last 20 trading days of 15-minute price, volume, and VWAP data. Price is trading 2.7% below the recent estimated cost basis of 467.44, so the recent structure is still leaning under pressure. Price is in the lower half of the main cost band (451.69 to 458.80), so price support and pullback behavior matter more than immediate upside follow-through. The higher up selling area sits around 462.20 to 465.90, and overhead supply looks fairly concentrated there. Roughly 73% of recent positioning remains under water, so rebound attempts can still run into supply from trapped holders. From a trading point of view, the main question is whether rebounds remain healthy enough to reach and absorb the higher overhead supply zone.
Short Interest & Covering Risk for VRTX
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is within its typical range, with no clear imbalance between buyers and sellers. (Historical percentile: 50%)
Structure Analysis
VRTX Short positioning looks normal. Current days to cover is 3.5 trading days, meaning short positions would unwind somewhat slower than average. Short covering is likely to have a normal impact on price moves. No meaningful structural fragility is currently detected (Fragility Score 24/100, DTC percentile 100%) and liquidity contracting meaningfully (volume -20%). Positioning is historically elevated, although price and liquidity conditions do not yet confirm structural fragility. Short positioning is at extreme historical levels.
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
Days-to-Cover is elevated versus its own history, but absolute short interest remains moderate. Average trading volume is weakening, indicating contracting liquidity. Price action is compressing (range is tightening), which can make breaks more sensitive. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-02-27 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.